Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged release tablets (RINVOQ®▼) for treating severe rheumatoid arthritis

CCG Approval Status:

Date Added: 28 - Jan - 2021
Body System:
Red

The Pan Mersey Area Prescribing Committee recommends the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ®▼), by specialists only, for treating severe rheumatoid arthritis in accordance with NICE TA665.